Literature DB >> 24829832

Pulmonary edema in myasthenic crisis.

Uttara Swati Anand1, Stalin Viswanathan2, Jayanthi Arulneyam3.   

Abstract

We report a previously asymptomatic 50-year-old lady who came with myasthenic crisis as initial presentation of myasthenia gravis. She developed pulmonary edema following intravenous immunoglobulin administration and had ischemic changes in ECG and left ventricular dysfunction on echocardiography. She improved with diuretics, dobutamine, and fluid restriction alone. This is the first report in English-language medical literature describing the association between myasthenic crisis and likely takotsubo cardiomyopathy-related pulmonary edema following intravenous immunoglobulin administration.

Entities:  

Year:  2013        PMID: 24829832      PMCID: PMC4010025          DOI: 10.1155/2013/863620

Source DB:  PubMed          Journal:  Case Rep Crit Care        ISSN: 2090-6420


1. Introduction

Myasthenia gravis (MG) is an antibody-mediated neurological disorder that affects the neuromuscular junction [1]. Myasthenic crisis is characterized by respiratory failure that requires mechanical ventilation [2]. Takotsubo cardiomyopathy is defined as a profound but reversible left ventricular dysfunction in the absence of coronary artery disease [3]. We present a 50-year-old lady with myasthenic crisis (MC), who developed pulmonary oedema following intravenous immunoglobulin (IVIG) and was found to have features suggestive of takotsubo cardiomyopathy (TC).

2. Case

She had had cough, rhinorrhoea, headache, myalgias, and fever for 10 days and presented to another hospital with fatigue of a week's duration, breathlessness, slurring of speech, and nasal regurgitation of liquids for two days. She was intubated and then transferred to our institution. On admission, she was conscious and afebrile with tachycardia (110/min), tachypnoea (22/min), and normal blood pressure. Cardiovascular and respiratory system examination was otherwise normal. Neurologically, she had flaccid quadriparesis (2/5), floppy neck, and bilateral facial nerve paralysis without ocular weakness or bladder incontinence. Chest radiograph (CXR), electrocardiogram (ECG), renal and liver function tests, and haemogram were normal. An initial diagnosis of Guillain-Barre syndrome was made and intravenous immunoglobulin (IVIG) was initiated at a dose of 0.4 g/kg/day. On the second day she had asymmetrical ptosis; 1 mg neostigmine administration led to improvement in ptosis and muscle power (4-/5) and neostigmine 30 mg every 4th hour was continued thereafter. Later during the day, tachycardia, tachypnoea, hypotension (96/60 mmHg), and left-sided infra-axillary crackles were observed. Chest radiograph revealed infiltrates in the left mid-zones (Figure 1(a)); ECG showed occasional VPCs (Figure 2(a)), and her total leukocyte counts were 20 × 109/L. Respiratory alkalosis was seen on arterial blood gas (ABG) analysis. Ceftriaxone, metronidazole, and levofloxacin were administered with a diagnosis of probable aspiration pneumonia; intravenous fluids were infused to maintain CVP of ~10 cm saline. Eight hours later her endotracheal tube was filled with frothy sputum and her tachypnea worsened. A repeat CXR revealed bilateral hilar infiltrates (Figure 1(b)), while ST depression and T-wave inversion were observed in the lateral leads (Figure 2(b)). IVIG was discontinued on day 3 due to financial constraints. Echocardiography showed hypokinetic anterior wall, distal septum and apex with an ejection fraction of 35%; creatine kinase MB (CK-MB) was 21U and Trop-I was negative. Her relatives did not provide consent to subject the patient for a coronary angiography; stress thallium scintigraphy was unavailable in our hospital. She improved thereafter with dobutamine, diuretics, and fluid restriction following which her CXR showed improvement. An electromyogram and repetitive nerve stimulation performed on day 4 confirmed the diagnosis of myasthenia gravis. ECG normalized on the fifth day. She was found to be ANA and ds-DNA positive, while the thyroid profile was normal. Twenty-four-hour urinary protein was 235 mg. She did not satisfy any other ACR criteria for SLE. Contrast CT for thymoma was noncontributory. We did not have facility for testing autoantibodies for MG. She was extubated 10 days after admission and was discharged home on oral prednisolone and neostigmine. Echocardiography prior to her discharge revealed an ejection fraction of 55% with no regional wall motion abnormalities.
Figure 1

(a) ECG showing VPCs. (b) ECG eight hours later with T-wave inversion and ST depression in leads I, aVL, V5, and V6.

Figure 2

(a) CXR revealing left hilar infiltrates. (b) CXR eight hours later with bilateral hilar infiltrates. (c) CXR 24 hours later with reduction in bilateral hilar infiltrates following diuretics and dobutamine.

3. Discussion

A dysfunctional left ventricle resembles a “takotsubo,” a narrow-necked pot used to trap octopuses. There are ten reports (between 2005 and 2013) detailing the association of MG and TC, with only five in English medical literature [3]. Three reports from Japan are available—the first following plasmapheresis to treat MC, the second after disopyramide therapy to treat atrial fibrillation (reported in English literature), and the last that developed after thymectomy [3, 4]. The Spanish patient presented with respiratory failure and takotsubo cardiomyopathy and was subsequently diagnosed with myasthenic crisis, while the patient from Brazil was a known case of MG and developed crisis that was treated with plasmapheresis [5, 6]. Among the cases reported in English literature, none of them had prior therapy with intravenous immunoglobulins [2, 4, 7, 8]. Two of them had simultaneous onset of takotsubo cardiomyopathy and myasthenic crisis [2, 9]. Our patient presented with myasthenic crisis as initial presentation of MG. She had no ocular symptoms or signs initially, leading us to suspect a different diagnosis. She developed asymmetric pulmonary edema that was treated as aspiration pneumonia initially. IVIG was discontinued after three days due to financial constraints. IVIG can itself cause myocardial infarction and cerebrovascular events as described in some reports. But some of those patients also had risk factors for coronary artery disease. IVIG in myasthenia crisis had caused non-ST elevation myocardial infarction [10]. That patient did not undergo catheterization and had no coronary risk factors; her thallium scan and CT revealed no coronary lesions [5]. IVIG can cause hyperviscosity and is hypothesized to cause coronary vasospasm due to release of cytokines and can cause elevations in catecholamines [10]. Neostigmine in another report was described to precipitate noncardiogenic pulmonary edema neostigmine in our patient was continued even after pulmonary edema without further worsening [11]. Another feature of our patient was the coexistence of SLE autoantibodies and proteinuria with MG. Our patient had clinical features of probable TC by virtue of being an older female, with physical and emotional stress of paralysis, hospitalization and mechanical ventilation, IVIG therapy, severe cardiorespiratory symptoms, and signs proportional to echocardiography but dissociated with the severity of ECG changes and cardiac enzymes which would be unlikely in ischemic heart disease. ECG normalized in 48 hours and echocardiography within 10 days. Possibly, IVIG may have a role in inducing TC due to its effects on the heart as seen in other cases although lack of angiography is a severe limitation in our case study. The pulmonary edema may be partly contributed by a neurogenic cause-myasthenia gravis itself. Thus, our patient had probable TC (due to lack of angiographic evidence) following MG and a combination of factors especially IVIG and critical care.

4. Conclusion

We report the first patient of MC with probable TC precipitated by immunoglobulins in English-language medical literature. Patients with MG are at potential risk of developing TC due to various physical and emotional stresses that they are subjected to during the course of their treatment. This risk is compounded by the fact that IVIG could also lead to TC by its effects on the heart. Hence, careful clinical and electrocardiographic monitoring is essential in all MG patients on IVIG therapy and coronary artery evaluation may be required prior to IVIG in such patients.
  11 in total

1.  Broken heart syndrome in myasthenia gravis.

Authors:  Vibhav Bansal; Mayank M Kansal; Julie Rowin
Journal:  Muscle Nerve       Date:  2011-12       Impact factor: 3.217

2.  Recurrent takotsubo cardiomyopathy precipitated by myasthenic crisis.

Authors:  Chun Pong Wong; Pow Li Chia
Journal:  Int J Cardiol       Date:  2011-07-20       Impact factor: 4.164

3.  Non-ST Elevation Myocardial Infraction after High Dose Intravenous Immunoglobulin Infusion.

Authors:  Meir Mizrahi; Tomer Adar; Efrat Orenbuch-Harroch; Yair Elitzur
Journal:  Case Rep Med       Date:  2010-02-22

Review 4.  Neuromuscular disorders and Takotsubo syndrome.

Authors:  Josef Finsterer; Claudia Stöllberger
Journal:  Int J Cardiol       Date:  2013-05-16       Impact factor: 4.164

5.  [Myasthenic crisis and Takotsubo syndrome: a non-chance relationship].

Authors:  S Mayor-Gomez; F Lacruz; D Ezpeleta
Journal:  Rev Neurol       Date:  2012-12-16       Impact factor: 0.870

6.  [Transient ventricular dysfunction (Takotsubo cardiomyopathy)].

Authors:  José Marconi Almeida de Sousa; Marcos Knobel; Gustavo Buchelle; José Augusto M de Sousa; Cláudio H Fisher; Daniel Born; Nelson Akamine; Elias Knobel
Journal:  Arq Bras Cardiol       Date:  2005-05-02       Impact factor: 2.000

7.  Tako-tsubo cardiomyopathy in a patient with myasthenia gravis crisis: a rare clinical association.

Authors:  Sasidharan Bijulal; Sivadasanpillai Harikrishnan; Narayanan Namboodiri; Valaparambil K Ajitkumar; Deepak Gupta; P S Mathuranath
Journal:  BMJ Case Rep       Date:  2009-02-16

8.  Severe respiratory failure and torsades de pointes induced by disopyramide in a patient with myasthenia gravis.

Authors:  Kayo Hirose; Hiroshi Yamaguchi; Yasushi Oshima; Masahito Choraku; Akira Hirono; Nobuyuki Takamori; Katsuya Tamura
Journal:  Intern Med       Date:  2008-10-01       Impact factor: 1.271

9.  Non-cardiogenic pulmonary oedema after neostigmine given for reversal: A report of two cases.

Authors:  Lalit Kumar Raiger; Udita Naithani; Bhavani S Vijay; Pradeep Gupta; Vaibhav Bhargava
Journal:  Indian J Anaesth       Date:  2010-07

Review 10.  Current and future standards in treatment of myasthenia gravis.

Authors:  Ralf Gold; Christiane Schneider-Gold
Journal:  Neurotherapeutics       Date:  2008-10       Impact factor: 7.620

View more
  6 in total

1.  Takotsubo Cardiomyopathy Mimicking Myocardial Infarction in a Man with Myasthenic Crisis: A Case Report and Literature Review.

Authors:  Taylor M Douglas; Perry Wengrofsky; Syed Haseeb; Eric Kupferstein; Pramod Theetha Kariyanna; Jacob Schwartz; Louis Salciccioli; Samy I McFarlane
Journal:  Am J Med Case Rep       Date:  2018-10-11

2.  Myasthenic crisis-induced Takotsubo cardiomyopathy in an elderly man: A case report of an underestimated but deadly combination.

Authors:  Yvonne Kuo; Thomas H Ottens; Ivo van der Bilt; Ruud Wm Keunen; Sakir Akin
Journal:  World J Cardiol       Date:  2021-01-26

3.  A Case Report and 31-Case Study: Does Takotsubo Cardiomyopathy in Myasthenia Gravis Patients Have a High Mortality Rate?

Authors:  Scott Gayfield; Joshua Busken; Sarmed Mansur
Journal:  Cureus       Date:  2022-08-31

4.  A Case Report of Recurrent Takotsubo Cardiomyopathy in a Patient during Myasthenia Crisis.

Authors:  Anusha Battineni; Naresh Mullaguri; Shail Thanki; Anand Chockalingam; Raghav Govindarajan
Journal:  Case Rep Crit Care       Date:  2017-10-19

5.  Defining Features of Patients who Develop Takotsubo Cardiomyopathy during Myasthenic Crisis: A Systematic Review of Case Studies.

Authors:  Pramod Theetha Kariyanna; Bayu Sutarjono; Apoorva Jayarangaiah; Remi Okwechime; Amog Jayarangaiah; Perry Wengrofsky; Isabel M McFarlane
Journal:  Am J Med Case Rep       Date:  2019-07-19

6.  Takotsubo syndrome in patients with myasthenia gravis: a systematic review of previously reported cases.

Authors:  Devarajan Rathish; Minuri Karalliyadda
Journal:  BMC Neurol       Date:  2019-11-12       Impact factor: 2.474

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.